GeoVax Labs (NASDAQ:GOVX) Announces Quarterly Earnings Results

GeoVax Labs (NASDAQ:GOVX) posted its earnings results on Wednesday. The company reported $1.85 EPS for the quarter, FiscalAI reports.

GeoVax Labs Price Performance

GOVX opened at $1.23 on Friday. The stock’s 50 day moving average price is $1.62 and its 200 day moving average price is $6.37. The stock has a market cap of $2.24 million, a P/E ratio of -0.03 and a beta of 3.81. GeoVax Labs has a 12 month low of $1.14 and a 12 month high of $34.75.

Hedge Funds Weigh In On GeoVax Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOVX. Jane Street Group LLC bought a new position in GeoVax Labs during the 1st quarter valued at $27,000. Sabby Management LLC bought a new position in GeoVax Labs during the 3rd quarter valued at $313,000. Armistice Capital LLC bought a new position in GeoVax Labs during the 3rd quarter valued at $253,000. Hudson Bay Capital Management LP bought a new position in GeoVax Labs during the 3rd quarter valued at $47,000. Finally, Renaissance Technologies LLC bought a new position in GeoVax Labs during the 4th quarter valued at $104,000. 6.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on GOVX shares. Wall Street Zen cut shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.